US 5,696,233 AGrant

Orphan Steroid Hormone Receptors

Issue Date:1997-12-09

•20 Claims

•1 Drawing Sheets

Abstract

Novel members of the steroid/thyroid superfamily of receptors are described. DNA sequences encoding same, expression vectors containing such DNA and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel receptors of the invention, and various uses thereof.

Metadata

Assignee

The Salk Institute for Biological Studies

Inventors

Ronald M. Evans
David J. Mangelsdorf
Estelita S. Ong
Anthony E. Oro
Uwe K. Borgmeyer
Vincent Giguere
Tso-Pang Yao

Application Information

Application Number:US 4636945

Filing Date:1995-06-05

Priority Date:1991-09-17

Art Unit:188

Classifications

IPC:

C07K 1472

Field of Search:

530350;399;358

Patent Drawings (1 sheets)

Description

FIELD OF THE INVENTION

The present invention relates to novel steroid-hormone or steroid-hormone like receptor proteins, genes encoding such proteins, and methods of making and using such proteins. In a particular aspect, the present invention relates to bioassay systems for determining the selectivity of interaction between ligands and steroid-hormone or steroid-hormone like receptor proteins.

BACKGROUND OF THE INVENTION

Transcriptional regulation of development and homeostasis in complex eukaryotes, including humans and other mammals, birds, fish, insects, and the like, is controlled by a wide variety of regulatory substances, including steroid and thyroid hormones. These hormones exert potent effects on development and differentiation of phylogenetically diverse organisms. The effects of hormones are mediated by interaction with specific, high affinity binding proteins referred to as receptors.

The ability to identify additional compounds which are able to affect transcription of genes which are responsive to steroid hormones or metabolites thereof, would be of significant value in identifying compounds of potential therapeutic use. Further, systems useful for monitoring solutions, body fluids, and the like, for the presence of steroid hormones or metabolites thereof, would be of value in medical diagnosis, as well as for various biochemical applications.

A number of receptor proteins, each specific for one of several classes of cognate steroid hormones e.g., estrogens (estrogen receptor), progesterones (progesterone receptor), glucocorticoid (glucocorticoid receptor), androgens (androgen receptor), aldosterones (mineralocorticoid receptor), vitamin D (vitamin D receptor)!, retinoids (e.g., retinoic acid receptor) or for cognate thyroid hormones (e.g., thyroid hormone receptor), are known. Receptor proteins have been found to be distributed throughout the cell population of complex eukaryotes in a tissue specific fashion.

Molecular cloning studies have made it possible to demonstrate that receptors for steroid, retinoid and thyroid hormones are all structurally related and comprise a superfamily of regulatory proteins. These regulatory proteins are capable of modulating specific gene expression in response to hormone stimulation by binding directly to cis-acting elements. Structural comparisons and functional studies with mutant receptors have revealed that these molecules are composed of a series of discrete functional domains, most notably, a DNA-binding domain that is composed typically of 66-68 amino acids, including two zinc fingers and an associated carboxy terminal stretch of approximately 250 amino acids, which latter region comprises the ligand-binding domain.

An important advance in the characterization of this superfamily of regulatory proteins has been the delineation of a growing list of gene products which possess the structural features of hormone receptors. This growing list of gene products has been isolated by low-stringency hybridization techniques employing DNA sequences encoding previously identified hormone receptor proteins.

It is known that steroid or thyroid hormones, protected forms thereof, or metabolites thereof, enter cells and bind to the corresponding specific receptor protein, initiating an allosteric alteration of the protein. As a result of this alteration, the complex of receptor and hormone (or metabolite thereof) is capable of binding to certain specific sites on chromatin with high affinity.

It is also known that many of the primary effects of steroid and thyroid hormones involve increased transcription of a subset of genes in specific cell types.

A number of steroid hormone- and thyroid hormone-responsive transcriptional control units have been identified. These include the mouse mammary tumor virus 5'-long terminal repeat (MTV LTR), responsive to glucocorticoid, aldosterone and androgen hormones; the transcriptional control units for mammalian growth hormone genes, responsive to glucocorticoids, estrogens and thyroid hormones; the transcriptional control units for mammalian prolactin genes and progesterone receptor genes, responsive to estrogens; the transcriptional control units for avian ovalbumin genes, responsive to progesterones; mammalian metallothionein gene transcriptional control units, responsive to glucocorticoids; and mammalian hepatic .alpha..sub.2u -globulin gene transcriptional control units, responsive to androgens, estrogens, thyroid hormones, and glucocorticoids.

A major obstacle to further understanding and more widespread use of the various members of the steroid/thyroid superfamily of hormone receptors has been a lack of availability of the receptor proteins, in sufficient quantity and sufficiently pure form, to allow them to be adequately characterized. The same is true for the DNA gene segments which encode them. Lack of availability of these DNA segments has prevented in vitro manipulation and in vivo expression of the receptor-encoding genes, and consequently the knowledge such manipulation and expression would yield.

In addition, a further obstacle to a more complete understanding and more widespread use of members of the steroid/thyroid receptor superfamily is the fact that additional members of this superfamily remain to be discovered, isolated and characterized.

The present invention is directed to overcoming these problems of short supply of adequately purified receptor material, lack of DNA segments which encode such receptors and increasing the number of identified and characterized hormone receptors which are available for use.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have discovered novel members of the steroid/thyroid superfamily of receptors. The novel receptors of the present invention are soluble, intracellular, nuclear (as opposed to cell surface) receptors, which are activated to modulate transcription of certain genes in animal cells when the cells are exposed to ligands therefor. The nuclear receptors of the present invention differ significantly from known steroid receptors, both in primary sequence and in responsiveness to exposure of cells to various ligands, e.g., steroids or steroid-like compounds.

Also provided in accordance with the present invention are DNAs encoding the receptors of the present invention, including expression vectors for expression thereof in animal cells, cells transformed with such expression vectors, cells co-transformed with such expression vectors and reporter vectors (to monitor the ability of the receptors to modulate transcription when the cells are exposed to a compound which interacts with the receptor); and methods of using such co-transformed cells in screening for compounds which are capable of leading to modulation of receptor activity.

Further provided in accordance with the present invention are DNA and RNA probes for identifying DNAs encoding additional steroid receptors.

In accordance with yet another embodiment of the invention, there is provided a method for making the receptors of the invention by expressing DNAs which encode the receptors in suitable host organisms.

The novel receptors and DNAs encoding same can be employed for a variety of purposes. For example, novel receptors of the present invention can be included as part of a panel of receptors which are screened to determine the selectivity of interaction of proposed agonists or antagonists and other receptors. Thus, a compound which is believed to interact selectively, for example, with the glucocorticoid receptor, should not have any substantial effect on any other receptors, including those of the present invention. Conversely, if such a proposed compound does interact with one or more of the invention receptors, then the possibility of side reactions caused by such compound is clearly indicated.

BRIEF DESCRIPTION OF THE FIGURE

FIG. 1 is a schematic diagram correlating the relationship between the alternate spliced variants of invention receptor XR1.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided DNAs encoding a polypeptide characterized by having a DNA binding domain comprising about 66 amino acids with 9 cysteine (Cys) residues, wherein said DNA binding domain has:

(i) less than about 70% amino acid sequence identity with the DNA binding domain of human retinoic acid receptor-alpha (hRAR-alpha);

(ii) less than about 60% amino acid sequence identity with the DNA binding domain of human thyroid receptor-beta (hTR-beta);

(iii) less than about 50% amino acid sequence identity with the DNA binding domain of human glucocorticoid receptor (hGR); and

(iv) less than about 65% amino acid sequence identity in with the DNA binding domain of human retinoid X receptor-alpha (hRXR-alpha).

Alternatively, DNAs of the invention can be characterized with respect to percent amino acid sequence identity of the ligand binding domain of polypeptides encoded thereby, relative to amino acid sequences of previously characterized receptors. As yet another alternative, DNAs of the invention can be characterized by the percent overall amino acid sequence identity of polypeptides encoded thereby, relative to amino acid sequences of previously characterized receptors.

Thus, DNAs of the invention can be characterized as encoding polypeptides having, in the ligand binding domain:

(i) less than about 35% amino acid sequence identity with the ligand binding domain of hRAR-alpha;

(ii) less than about 30% amino acid sequence identity with the ligand binding domain of hTR-beta;

(iii) less than about 25% amino acid sequence identity with the ligand binding domain of hGR; and

(iv) less than about 30% amino acid sequence identity with the ligand binding domain of hRXR-alpha.

DNAs of the invention can be further characterized as encoding polypeptides having an overall amino acid sequence identity of:

(i) less than about 35% relative to hRAR-alpha;

(ii) less than about 35% relative to hTR-beta;

(iii) less than about 25% relative to hGR; and

(iv) less than about 35% relative to hRXR-alpha.

Specific receptors contemplated for use in the practice of the present invention include:

"XR1" (variously referred to herein as receptor "XR1", "hXR1", "hXR1.pep" or "verHT19.pep";

wherein the prefix "h" indicates the clone is of human origin), a polypeptide characterized as

having a DNA binding domain comprising:

(i) about 68% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 59% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 45% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 2 for a specific amino acid sequence representative of XR1, as well as Sequence ID No. 1 which is an exemplary nucleotide sequence encoding XR1. In addition, Sequence ID Nos. 4 and 6 present alternate amino terminal sequences for the clone referred to as XR1 (the variant referred to as verht3 is presented in Sequence ID No. 4 (an exemplary nucleotide sequence encoding such variant presented in Sequence ID No. 3), and the variant referred to as verhr5 is presented in Sequence ID No. 6 (an exemplary nucleotide sequence encoding such variant presented in Sequence ID No. 5);

"XR2" (variously referred to herein as receptor "XR2", "hXR2" or "hXR2.pep"), a polypeptide characterized as having a DNA binding domain comprising:

(i) about 55% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 56% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 52% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 8 for a specific amino acid sequence representative of XR2, as well as Sequence ID No. 7 which is an exemplary nucleotide sequence encoding XR2;

"XR4" (variously referred to herein as receptor "XR4", "mXR4" or "mXR4.pep"; wherein the prefix "m" indicates the clone is of mouse origin), a polypeptide characterized as having a DNA binding domain comprising:

(i) about 62% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 58% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 48% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 62% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 10 for a specific amino acid sequence representative of XR4, as well as Sequence ID No. 9 which is an exemplary nucleotide sequence encoding XR4;

"XR5" (variously referred to herein as receptor "XR5", "mXR5" or "mXR5.pep"), a polypeptide characterized as having a DNA binding domain comprising:

(i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 52% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 44% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 61% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 12 for a specific amino acid sequence representative of XR5, as well as Sequence ID No. 11 which is an exemplary nucleotide sequence encoding XR5; and

"XR79" (variously referred to herein as "XR79", "dXR79" or "dXR79.pep"; wherein the prefix "d" indicates the clone is of Drosophila origin), a polypeptide characterized as having a DNA binding domain comprising:

(i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 55% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 14 for a specific amino acid sequence representative of XR79, as well as Sequence ID No. 13 which is an exemplary nucleotide sequence encoding XR79.

The receptor referred to herein as "XR1" is observed as three closely related proteins, presumably produced by alternate splicing from a single gene. The first of these proteins to be characterized (referred to as "verht19") comprises about 548 amino acids, and has a M.sub.r of about 63 kilodalton. Northern analysis indicates that a single mRNA species corresponding to XR1 is highly expressed in the brain. A variant of verht19 (alternatively referred to as "verht3", XR1' or XR1prime) is further characterized as comprising about 556 amino acids, and having a M.sub.r of about 64 kilodalton. Yet another variant of verht19 (alternatively referred to as "verhr5", XR1" or XR1prim2) is further characterized as comprising about 523 amino acids, and having a M.sub.r of about 60 kilodalton. The interrelationship between these three variants of XR1 is illustrated schematically in FIG. 1.

The receptor referred to herein as "XR2" is further characterized as a protein comprising about 440 amino acids, and having a M.sub.r of about 50 kilodalton. Northern analysis indicates that a single mRNA species (.about.1.7 kb) corresponding to XR2 is expressed most highly in liver, kidney, lung, intestine and adrenals of adult male rats. Transactivation studies (employing chimeric receptors containing the XR2 DNA binding domain and the ligand binding domain of a prior art receptor) indicate that XR2 is capable of binding to TREt. In terms of amino acid sequence identity with prior art receptors, XR2 is most closely related to the vitamin D receptor (39% overall amino acid sequence identity, 17% amino acid identity in the amino terminal domain of the receptor, 53% amino acid identity in the DNA binding domain of the receptor and 37% amino acid identity in the ligand binding domain of the receptor).

The receptor referred to herein as "XR4" is further characterized as a protein comprising about 439 amino acids, and having a M.sub.r of about 50 kilodalton. In terms of amino acid sequence identity with prior art receptors, XR4 is most closely related to the peroxisome proliferator-activated receptor (62% overall amino acid sequence identity, 30% amino acid identity in the amino terminal domain of the receptor, 86% amino acid identity in the DNA binding domain of the receptor and 64% amino acid identity in the ligand binding domain of the receptor). XR4 is expressed ubiquitously and throughout development (as determined by in situ hybridization).

The receptor referred to herein as "XR5" is further characterized as a protein comprising about 556 amino acids, and having a M.sub.r of about 64 kilodalton. In situ hybridization reveals widespread expression throughout development. High levels of expression are observed in the embryonic liver around day 12, indicating a potential role in haematopoiesis. High levels are also found in maturing dorsal root ganglia and in the skin. In terms of amino acid sequence identity with prior art receptors, XR5 is most closely related to the rat nerve growth factor induced protein-B (NGFI-B) receptor. With respect to NGFI-B, XR5 has 29% overall amino acid sequence identity, 15% amino acid identity in the amino terminal domain of the receptor, 52% amino acid identity in the DNA binding domain of the receptor and 29% amino acid identity in the ligand binding domain of the receptor.

The receptor referred to herein as "XR79" is further characterized as a protein comprising about 601 amino acids, and having a M.sub.r of about 66 kilodalton. Whole mount in situ hybridization reveals a fairly uniform pattern of RNA expression during embryogenesis. Northern blot analysis indicates that a 2.5 kb transcript corresponding to XR79 is present in RNA throughout development. The levels of XR79 mRNA are highest in RNA from 0-3 hour old embryos, i.e., maternal product, and lowest in RNA from the second instar larvae (L2 stage). In situ hybridization reveals that XR79 is distributed relatively uniformly at different stages of embryogenesis. In terms of amino acid sequence identity with prior art receptors, XR79 is most closely related to the mammalian receptor TR2 (see Chang and Kokontis in Biochemical and Biophysical Research Communications 155: 971-977 (1988)), as well as members of the coup family, i.e., ear2, coup(ear3), harp-1. With respect to TR2, XR79 has 33% overall amino acid sequence identity, 16% amino acid identity in the amino terminal domain of the receptor, 74% amino acid identity in the DNA binding domain of the receptor and 28% amino acid identity in the ligand binding domain of the receptor. With respect to coup (ear3) (see Miyajima et al., in Nucl Acids Res 16: 11057-11074 (1988), XR79 has 32% overall amino acid sequence identity, 21% amino acid identity in the amino terminal domain of the receptor, 62% amino acid identity in the DNA binding domain of the receptor and 22% amino acid identity in the ligand binding domain of the receptor.

In accordance with a specific embodiment of the present invention, there is provided an expression vector which comprises DNA as previously described (or functional fragments thereof), and which further comprises:

at the 5'-end of said DNA, a promoter and a nucleotide triplet encoding a translational start codon, and

at the 3'-end of said DNA, a nucleotide triplet encoding a translational stop codon;

wherein said expression vector is operative in a cell in culture (e.g., yeast, bacteria, mammalian) to express the protein encoded by said DNA.

As employed herein, reference to "functional fragments" embraces DNA encoding portions of the invention receptors which retain one or more of the functional characteristics of steroid hormone or steroid hormone-like receptors, e.g., DNA binding properties of such receptors, ligand binding properties of such receptors, the ability to heterodimerize, nuclear localization properties of such receptors, phosphorylation properties of such receptors, transactivation domains characteristic of such receptors, and the like.

In accordance with a further embodiment of the present invention, there are provided cells in culture (e.g., yeast, bacteria, mammalian) which are transformed with the above-described expression vector.

In accordance with yet another embodiment of the present invention, there is provided a method of making the above-described novel receptors (or functional fragments thereof) by culturing the above-described cells under conditions suitable for expression of polypeptide product.

In accordance with a further embodiment of the present invention, there are provided novel polypeptide products produced by the above-described method.

In accordance with a still further embodiment of the present invention, there are provided chimeric receptors comprising at least an amino-terminal domain, a DNA-binding domain, and a ligand-binding domain,

wherein at least one of the domains thereof is derived from the novel polypeptides of the present invention; and

wherein at least one of the domains thereof is derived from at least one previously identified member of the steroid/thyroid superfamily of receptors e.g., glucocorticoid receptor (GR), thyroid receptors (TR), retinoic acid receptors (RAR), mineralocorticoid receptor (MR), estrogen receptor (ER), the estrogen related receptors (e.g., hERR1 or hERR2), retinoid X receptors (e.g., RXR.alpha., RXR.beta. or RXR.delta.), vitamin D receptor (VDR), aldosterone receptor (AR), progesterone receptor (PR), the ultraspiracle receptor (USP), nerve growth factor induced protein-B (NGFI-B), the coup family of transcription factors (COUP), peroxisome proliferator-activated receptor (PPAR), mammalian receptor TR2 (TR2), and the like.

In accordance with yet another embodiment of the present invention, there is provided a method of using polypeptides of the invention to screen for response elements and/or ligands for the novel receptors described herein. The method to identify compounds which act as ligands for receptor polypeptides of the invention comprising:

assaying for the presence or absence of reporter protein upon contacting of cells containing a chimeric form of said receptor polypeptide and reporter vector with said compound;

wherein said chimeric form of said receptor polypeptide comprises the ligand binding domain of said receptor polypeptide and the amino-terminal and DNA-binding domains of one or more previously identified members of the steroid/thyroid superfamily of receptors;

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a hormone response element which is responsive to the receptor from which the DNA-binding domain of said chimeric form of said receptor polypeptide is derived, and

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof, and thereafter

identifying those compounds which induce or block the production of reporter in the presence of said chimeric form of said receptor polypeptide.

The method to identify response elements for receptor polypeptides of the invention comprises:

assaying for the presence or absence of reporter protein upon contacting of cells containing a chimeric form of said receptor polypeptide and reporter vector with a compound which is a known agonist or antagonist for the receptor from which the ligand-binding domain of said chimeric form of said receptor polypeptide is derived;

wherein said chimeric form of said receptor polypeptide comprises the DNA-binding domain of the receptor polypeptide and the amino-terminal and ligand-binding domains of one or more previously identified members of the steroid/thyroid superfamily of receptors;

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a putative hormone response element, and

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof; and

identifying those response elements for which the production of reporter is induced or blocked in the presence of said chimeric form of said receptor polypeptide.

In accordance with yet another embodiment of the present invention, there is provided a DNA or RNA labeled for detection; wherein said DNA or RNA comprises a nucleic acid segment, preferably of at least 20 bases in length, wherein said segment has substantially the same sequence as a segment of the same length selected from the DNA segment represented by bases 21-1902, inclusive, of Sequence ID No. 1, bases 1-386, inclusive, of Sequence ID No. 3, bases 10-300, inclusive, of Sequence ID No. 5, bases 21-1615, inclusive, of Sequence ID No. 7, bases 21-2000, inclusive, of Sequence ID No. 9, bases 1-2450, inclusive, of Sequence ID No. 11, bases 21-2295, inclusive, of Sequence ID No. 13, or the complement of any of said segments.

In accordance with still another embodiment of the present invention, there are provided methods of testing compound(s) for the ability to regulate transcription-activating effects of a receptor polypeptide, said method comprising assaying for the presence or absence of reporter protein upon contacting of cells containing a receptor polypeptide and reporter vector with said compound;

wherein said receptor polypeptide is characterized by having a DNA binding domain comprising about 66 amino acids with 9 Cys residues, wherein said DNA binding domain has:

(i) less than about 70% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) less than about 60% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) less than about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) less than about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha; and

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a hormone response element, and

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof.

In accordance with a still further embodiment of the present invention, there is provided a method of testing a compound for its ability to selectively regulate the transcription-activating effects of a specific receptor polypeptide, said method comprising:

assaying for the presence or absence of reporter protein upon contacting of cells containing said receptor polypeptide and reporter vector with said compound;

wherein said receptor polypeptide is characterized by being responsive to the presence of a known ligand for said receptor to regulate the transcription of associated gene(s);

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a hormone response element, and

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof; and

assaying for the presence or absence of reporter protein upon contacting of cells containing chimeric receptor polypeptide and reporter vector with said compound;

wherein said chimeric receptor polypeptide comprises the ligand binding domain of a novel receptor of the present invention, and the DNA binding domain of said specific receptor; and thereafter

selecting those compounds which induce or block the production of reporter in the presence of said specific receptor, but are substantially unable to induce or block the production of reporter in the presence of said chimeric receptor.

The above-described methods of testing compounds for the ability to regulate transcription-activating effects of invention receptor polypeptides can be carried out employing methods described in U.S. Ser. No. 108,471; now U.S. Pat. No. 5,071,773; filed Oct. 20, 1987, the entire contents of which are hereby incorporated by reference herein.

As employed herein, the term "expression vector" refers to constructs containing DNA of the invention (or functional fragments thereof), plus all sequences necessary for manipulation and expression of such DNA. Such an expression vector will contain both a "translational start site" and a "translational stop site". Those of skill in the art can readily identify sequences which act as either translational start sites or translational stop sites.

Suitable host cells for use in the practice of the present invention include prokaroytic and eukaryote cells, e.g., bacteria, yeast, mammalian cells and the like.

Labeled DNA or RNA contemplated for use in the practice of the present invention comprises nucleic acid sequences covalently attached to readily analyzable species such as, for example, radiolabel (e.g., .sup.32 P, .sup.3 H, .sup.35 S, and the like), enzymatically active label, and the like.

The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLES

Example I

ISOLATION AND CHARACTERIZATION OF XR1

The KpnI/SacI restriction fragment (503bp) including the DNA-binding domain of hRAR-alpha-encoding DNA (See Giguere et al., Nature 330: 624-629 (1987); and commonly assigned U.S. patent application Ser. No. 276,536; now U.S. Pat. No. 4,981,784; filed Nov. 30, 1988; and European Patent Application Publication No. 0 325 849, all incorporated herein by reference) was nick-translated and used to screen a rat brain cDNA library (see DNA Cloning, A practical approach, Vol I and II, D. M. Glover, ed. (IRL Press (1985)) and a lambda-gt11 human liver cDNA library (Kwok et al., Biochem. 24: 556 (1985)) at low stringency. The hybridization mixture contained 35% formamide, 1.times. Denhardt's, 5.times. SSPE (1.times. SSPE=0.15M NaCl, 10 mM Na.sub.2 HPO.sub.4 1 mM EDTA), 0.1% SDS, 10% dextran sulfate, 100 .mu.g/ml denatured salmon sperm DNA and 10.sup.6 cpm of (.sup.32 P)-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42.degree. C., washed once at 25.degree. C. for 15 min with 2.times. SSC (1.times. SSC=0.15M NaCl, 0.015M sodium citrate), 0.1% SDS and then washed twice at 55.degree. C. for 30 min. in 2.times. SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70.degree. C. using an intensifying screen.

After several rounds of screening, a pure positive clone having an insert of about 2.1 kb is obtained from the rat brain cDNA library. Several positive clones are obtained from the human liver library. Sequence analysis of the positive rat brain clone indicates that this clone encodes a novel member of the steroid/thyroid superfamily of receptors. Sequence analysis of one of the positive human liver clones (designated "hL1", a 1.7 kb cDNA) indicates that this clone is the human equivalent of the rat brain clone, based on sequence homology.

The EcoRI insert of clone hL1 (labeled with .sup.32 P) is also used as a probe to screen a human testis cDNA library (Clonetech) and a human retina cDNA library (see Nathans et al., in Science 232: 193-202 (1986)). Hybridization conditions comprised a hybridization mixture containing 50% formamide, 1.times. Denhardt's, 5.times. SSPE, 0.1% SDS, 100 .mu.g/ml denatured salmon sperm DNA and 10.sup.6 cpm of (.sup.32 P)-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42.degree. C., washed once at 25.degree. C. for 15 min with 2.times. SSC (1.times. SSC=0.15M NaCl, 0.015M sodium citrate), 0.1% SDS and then washed twice at 55.degree. C. for 30 min. in 2.times. SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70.degree. C. using an intensifying screen.

After several rounds of screening, five (5) positive clones were obtained from the human retina cDNA library, and five (5) positive clones were obtained from the human testis cDNA library. Sequence analysis of two clones from the testis library indicates that these clones encode different isoforms of the same novel member of the steroid/thyroid superfamily of receptors (designated as "Verht19" and "Verht3"). Sequence analysis of one of the positive clones from the human retina library indicates that this clone is yet another isoform of the same novel member of the steroid/thyroid superfamily of receptors (designated "Verhr5"). The full length sequence of Verht19 is set forth herein as Sequence ID No. 1 (which includes an indication of where the splice site is for each of the variants, verht3 and verhr5). The amino-terminal sequence of verht3 and verhr5 are presented in Sequence ID Nos. 3 and 5, respectively. In addition, the interrelationship between each of these three isoforms is illustrated schematically in FIG. 1.

Example II

ISOLATION AND CHARACTERIZATION OF XR2

The KpnI/SacI restriction fragment (503bp) including the DNA-binding domain of hRAR-alpha-encoding DNA (See Giguere et al., Nature 330: 624 (1987); and commonly assigned U.S. patent application Ser. No. 276,536; now U.S. Pat. No. 4,981,784; filed Nov. 30, 1988; and European Patent Application Publication No. 0 325 849, all incorporated herein by reference) was nick-translated and used to screen a lambda-gt11 human liver cDNA library (Kwok et al., Biochem. 24: 556 (1985)) at low stringency. The hybridization mixture contained 35% formamide, 1.times. Denhardt's, 5.times. SSPE (1.times. SSPE=0.15M NaCl, 10 mM Na.sub.2 HPO.sub.4 1 mM EDTA), 0.1% SDS, 10% dextran sulfate, 100 mg/ml denatured salmon sperm DNA and 10.sup.6 cpm of (.sup.32 P)-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42.degree. C., washed once at 25.degree. C. for 15 min with 2.times. SSC (1.times. SSC=0.15M NaCl, 0.015 M sodium citrate), 0.1% SDS and then washed twice at 55.degree. C. for 30 min. in 2.times. SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70.degree. C. using an intensifying screen.

Positive clones were isolated, subcloned into pGEM vectors (Promega, Madison, Wis., USA), restriction mapped, and re-subcloned in various sized restriction fragments into M13mp18 and M13mp19 sequencing vectors. DNA sequence was determined by the dideoxy method with Sequenase.TM. sequencing kit (United States Biochemical, Cleveland, Ohio, USA) and analyzed by University of Wisconsin Genetics Computer Group programs (Devereux et al., Nucl. Acids Res. 12, 387 (1984)). Several clones of a unique receptor-like sequence were identified, the longest of which was designated lambda-HL1-1 (also referred to herein as XR2).

The DNA sequence of the resulting clone is set forth as Sequence ID No. 7.

Example III

ISOLATION AND CHARACTERIZATION OF XR4

A clone which encodes a portion of the coding sequence for XR4 was isolated from a mouse embryonic library by screening under low stringency conditions (as described above).

The library used was a lambda gt10 day 8.5 cDNA library having an approximate titer of 1.3.times.10.sup.10 /ml (derived from 8.5 day old embryonic material with as much of the amnion and extraembryonic tissues dissected away as possible). This library was prepared from poly A+ selected RNA (by oligo-dT priming), Gubler & Hoffman cloning methods (Gene 25: 263 (1983)), and cloned into the EcoRI site of lambda gt10.

The probe used was a mixture of radioactively labeled DNA derived from the DNA binding regions of the human alpha and beta retinoic acid receptors.

The DNA sequence of the resulting clone is set forth as Sequence ID No. 9.

Example IV

ISOLATION AND CHARACTERIZATION OF XR5

A clone which encodes a portion of the coding sequence for XR5 was isolated from a mouse embryonic library by screening under low stringency conditions (as described above).

The library used was the same lambda gt10 day 8.5 cDNA library described in the preceding example. Similarly, the probe used was the same mixture of radioactively labeled DNA described in the preceding example.

Only one of the clones isolated corresponds to a portion of the coding region for XR5. A 0.7 kb EcoRI fragment of this clone (designated as No. II-17) was subcloned into the bluescript pksII-Vector. Partial sequence analysis of this insert fragment shows homology to the DNA binding domain of the retinoic acid receptors.

The EcoRI-insert was used to rescreen a second library (a mouse lambda ZAPII day 6.5 cDNA library, prepared as described below) under high stringency conditions. A total of 21 phages were isolated and rescued into the psk-vector. Partial sequencing allowed inserts from 13 of these phages to be identified as having sequences which overlap with XR5 II-17. The clone with the longest single EcoRI-insert was sequenced, revealing an open reading frame of 556 amino acids. This sequence was extended further upstream by 9bp from the furthest 5'-reaching clone.

The DNA sequence of the resulting clone is set forth as Sequence ID No. 11.

The day 6.5 cDNA library, derived from 6.5 day old mouse embryonic material was prepared from poly A+ selected RNA (by oligo-dT priming), and cloned into the EcoRI site of lambda gt10.

Example V

ISOLATION AND CHARACTERIZATION OF XR79

The 550 bp BamHI restriction fragment, including the DNA-binding domain of mouse RAR-beta-encoding DNA (See Hamada et al., Proc. Natl. Acad. Sci. 86: 8289 (1989); incorporated by reference herein) was nick-translated and used to screen a Lambda-ZAP cDNA library comprising a size selected Drosophila genomic library (.about.2-5 kb, EcoRI restricted) at low stringency. The hybridization mixture contained 35% formamide, 1.times. Denhardt's, 5.times. SSPE (1.times. SSPE=0.15M NaCl, 10 mM Na.sub.2 HPO.sub.4 1 mM EDTA), 0.1% SDS, 10% dextran sulfate, 100 mg/ml denatured salmon sperm DNA and 10.sup.6 cpm of (.sup.32 P)-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42.degree. C., washed once at 25.degree. C. for 15 min with 2.times. SSC (1.times. SSC=0.15M NaCl, 0.015M sodium citrate), 0.1% SDS and then washed twice at 55.degree. C. for 30 min. in 2.times. SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70.degree. C. using an intensifying screen.

After several rounds of screening, a pure positive clone having an insert of about 3.5 kb is obtained from the Drosophila genomic library. This genomic clone was then used to screen a Drosophila imaginal disc lambda gt10 cDNA library (obtained from Dr. Charles Zuker; see DNA Cloning, A practical approach, Vol I and II, D. M. Glover, ed. (IRL Press (1985)). Hybridization conditions comprised a hybridization mixture containing 50% formamide, 1.times. Denhardt's, 5.times. SSPE, 0.1% SDS, 100 .mu.g/ml denatured salmon sperm DNA and 10.sup.6 cpm of (.sup.32 P)-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42.degree. C., washed once at 25.degree. C. for 15 min with 2.times. SSC (1.times. SSC=0.15M NaCl, 0.015M sodium citrate), 0.1% SDS and then washed twice at 55.degree. C. for 30 min. in 2.times. SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70.degree. C. using an intensifying screen.

Sequence analysis of the positive cDNA clone indicates that this clone encodes another novel member of the steroid/thyroid superfamily of receptors (designated "XR79", a 2.5 kb cDNA) See Sequence ID No. 13 for the DNA sequence of the resulting clone.

The 2.5 kb cDNA encoding XR79 was nick-translated and used as a probe for a nitrocellulose filter containing size-fractionated total RNA, isolated by standard methods from Drosophila melanogaster of different developmental stages. The probe hybridized to a 2.5 kb transcript which was present in RNA throughout development. The levels were highest in RNA from 0-3 hour old embryos and lowest in RNA from second instar larvae. The same 2.5 kb cDNA was nick translated using biotinylated nucleotides and used as a probe for in situ sybridization to whole Drosophila embryos (Tautz and Pfeifle, Chromosoma 98: 81-85 (1989)). The RNA distribution appeared relatively uniform at different stages of embryogenesis.

Example VI

SEQUENCE COMPARISONS OF INVENTION RECEPTORS WITH hRAR.alpha., hTR.beta., hGR, AND hRXR.alpha.

Amino acid sequences of XR1, hRAR-alpha (human retinoic acid receptor-alpha), hTR-beta (human thyroid hormone receptor-beta), hGR (human glucocorticoid receptor), and hRXR-alpha (human retinoid receptor-alpha) were aligned using the University of Wisconsin Genetics Computer Group program "Bestfit" (Devereux et al., supra). The percentage of amino acid identity between RX2 and the other receptors, i.e., in the 66-68 amino acid DNA binding domains and the ligand-binding domains, are summarized in Table 1 as percent amino acid identity.

Similarly, the amino acid sequences of invention receptors XR2, XR4, XR5, and XR79 were compared with human RAR-alpha (hRAR.alpha.), human TR-beta (hTR.beta.), human glucocorticoid (hGR) and human RXR-alpha (hRXR.alpha.). As done in Table 1, the percentage of amino acid identity between the invention receptors and the other receptors are summarized in Tables 2-5, respectively.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

SUMMARY OF SEQUENCES

Sequence ID No. 1 is a nucleotide sequence encoding novel receptor of the present invention designated as "hXR1 ".

Sequence ID No. 2 is the amino acid sequence deduced from the nucleotide sequence set forth in Sequence ID No. 1 (variously referred to herein as receptor "XR1", "hXR1", "hXR1.pep" or "verHT19.pep").

Sequence ID No. 3 is a nucleotide sequence encoding the amino-terminal portion of the novel receptor of the present invention designated as "hXR1prime".

Sequence ID No. 4 is the amino acid sequence deduced from the nucleotide sequence set forth in Sequence ID No. 3 (variously referred to herein as receptor "XR1prime", "hXR1prime", "hXR1prime.pep" or "verHT3.pep").

Sequence ID No. 5 is a nucleotide sequence encoding the amino-terminal portion of the novel receptor of the present invention designated as "hXR1prim2".

Sequence ID No. 6 is the amino acid sequence deduced from the nucleotide sequence set forth in Sequence ID No. 5 (variously referred to herein as receptor "XR1prim2", "hXR1prim2", "hXR1prim2.pep" or "verHr5.pep").

Sequence ID No. 7 is a nucleotide sequence encoding the novel receptor of the present invention designated as "hXR2".

Sequence ID No. 8 is the amino acid sequence deduced from the nucleotide sequence set forth in Sequence ID NO. 7 (variously referred to herein as receptor "XR2", "hXR2" or "hXR2.pep").

Sequence ID No. 9 is a nucleotide sequence encoding novel receptor of the present invention referred to herein as "mXR4".

Sequence ID No. 10 is the amino acid sequence deduced from the nucleotide sequence of Sequence ID No. 9 (variously referred to herein as receptor "XR4", "mXR4" or "mXR4.pep").

Sequence ID No. 11 is the nucleotide sequence encoding the novel receptor of the present invention referred to as "mXR5".

Sequence ID No. 12 is the amino acid sequence deduced from the nucleotide sequence of Sequence ID No. 11 (variously referred to herein as receptor "XR5", "mXR5" or "mXR5.pep").

Sequence ID No. 13 is the nucleotide sequence encoding the novel receptor of the present invention referred to as "dXR79".

Sequence ID No. 14 is the amino acid sequence deduced from the nucleotide sequence of Sequence ID No. 13 (variously referred to herein as "XR79", "dXR79" or "dXR79.pep").

Claims

That which is claimed is:

1. A polypeptide characterized by having a DNA binding domain comprising about 66 amino acids with 9 Cys residues, wherein said DNA binding domain is further characterized by the following amino acid sequence identity, relative to the DNA binding domains of hRAR-alpha, hTR-beta, hGR and hRXR-alpha, respectively: A. (i) about 68% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 59% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 45% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha; or B. (i) about 55% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 56% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 52% amino acid sequence identity with the DNA binding domain of hRXR-alpha; or C. (i) about 62% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 58% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 48% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 62% amino acid sequence identity with the DNA binding domain of hRXR-alpha; or D. (i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 52% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 44% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 61% amino acid sequence identity with the DNA binding domain of hRXR-alpha; or E. (i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 55% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

2. A polypeptide according to claim 1 wherein the DNA binding domain of said polypeptide has: (i) about 68% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 59% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 45% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

3. A polypeptide according to claim 2 wherein the ligand binding domain of said polypeptide has: (i) about 27% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 30% amino acid sequence identity with the ligand binding domain of hTR-beta; (iii) about 20% amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 22% amino acid sequence identity with the ligand binding domain of hRXR-alpha.

4. A polypeptide according to claim 3 wherein said polypeptide has an overall amino acid sequence identity of: (i) about 32% relative to hRAR-alpha; (ii) about 31% relative to hTR-beta; (iii) about 18% relative to hGR; and (iv) about 29% relative to hRXR-alpha.

5. A polypeptide according to claim 1 wherein the DNA binding domain of said polypeptide has: (i) about 55% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 56% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 52% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

6. A polypeptide according to claim 5 wherein the ligand binding domain of said polypeptide has: (i) about 32% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 29% amino acid sequence identity with the ligand binding domain of hTR-beta; (iii) about 20% amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 23% amino acid sequence identity with the ligand binding domain of hRXR-alpha.

7. A polypeptide according to claim 6 wherein said polypeptide has an overall amino acid sequence identity of: (i) about 33% relative to hRAR-alpha; (ii) about 31% relative to hTR-beta; (iii) about 24% relative to hGR; and (iv) about 27% relative to hRXR-alpha.

8. A polypeptide according to claim 1 wherein the DNA binding domain of said polypeptide has: (i) about 62% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 58% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 48% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 62% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

9. A polypeptide according to claim 8 wherein the ligand binding domain of said polypeptide has: (i) about 29% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 27% amino acid sequence identity with the ligand binding domain of hTR-beta; (iii) about 21% amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 28% amino acid sequence identity with the ligand binding domain of hRXR-alpha.

10. A polypeptide according to claim 9 wherein said polypeptide has an overall amino acid sequence identity of: (i) about 32% relative to hRAR-alpha; (ii) about 31% relative to hTR-beta; (iii) about 25% relative to hGR; and (iv) about 33% relative to hRXR-alpha.

11. A polypeptide according to claim 1 wherein the DNA binding domain of said polypeptide has: (i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 52% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 44% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 61% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

12. A polypeptide according to claim 11 wherein the ligand binding domain of said polypeptide has: (i) about 19% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 22% amino acid sequence identity with the ligand binding domain of hTR-beta; (iii) about 20% amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 27% amino acid sequence identity with the ligand binding domain of hRXR-alpha.

13. A polypeptide according to claim 12 wherein said polypeptide has an overall amino acid sequence identity of: (i) about 27% relative to hRAR-alpha; (ii) about 24% relative to hTR-beta; (iii) about 20% relative to hGR; and (iv) about 29% relative to hRXR-alpha.

14. A polypeptide according to claim 1 wherein the DNA binding domain of said polypeptide has: (i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha; (ii) about 55% amino acid sequence identity with the DNA binding domain of hTR-beta; (iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and (iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

15. A polypeptide according to claim 14 wherein the ligand binding domain of said polypeptide has: (i) about 18% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 20% amino acid sequence identity with the ligand binding domain of hTR-beta; (iii) about 20% amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 24% amino acid sequence identity with the ligand binding domain of hRXR-alpha.

16. A polypeptide according to claim 15 wherein said polypeptide has an overall amino acid sequence identity of: (i) about 24% relative to hRAR-alpha; (ii) about 28% relative to hTR-beta; (iii) about 18% relative to hGR; and (iv) about 33% relative to hRXR-alpha.

17. A polypeptide according to claim 1 wherein the ligand binding domain of said polypeptide is further characterized by the following amino acid sequence identity, relative to the ligand binding domains of hRAR-alpha, hTR-beta, hGR and hRXR-alpha, respectively: A (i) about 27% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 30% amino acid sequence identity with the ligand binding domain of hTR-beta; (iii) about 20amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 22% amino acid sequence identity with the ligand binding domain of hRXR-alpha; or B. (i) about 32% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 29% amino acid sequence identity with the ligand binding domain of hTR-beta; (iii) about 20% amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 23% amino acid sequence identity with the ligand binding domain of hRXR-alpha; or C. (i) about 29% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 27% amino acid sequence identity with the ligand binding domain of hTRt-beta; (iii) about 21% amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 28% amino acid sequence identity with the ligand binding domain of hRXR-alpha; or D. i) about 19% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 22% amino acid sequence identity with the ligand binding domain of hTR-beta; (iii) about 20% amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 27% amino acid sequence identity with the ligand binding domain of hRXR-alpha; or E. (i) about 18% amino acid sequence identity with the ligand binding domain of hRAR-alpha; (ii) about 20% amino acid sequence identity with the ligand binding domain of hTR-beta; (iii). about 20% amino acid sequence identity with the ligand binding domain of hGR; and (iv) about 24% amino acid sequence identity with the ligand binding domain of hRXR-alpha.

18. A polypeptide according to claim 1 wherein said polypeptide has an overall amino acid sequence identity, relative to hRAR-alpha, hTR-bea, hGR and hRXR-alpha, respectively of: A. (i) about 32% relative to hRAR-alpha; (ii) about 31% relative to hTR-beta; (iii) about 18% relative to hGR; and (iv) about 29% relative to hRXR-alpha; or B. (i) about 33% relative to hRAR-alpha; (ii) about 31% relative to hTR-beta; (iii) about 24% relative to hGR; and (iv) about 27relative to hRXR-alpha; or C. (i) about 32relative to hRAR-alpha. (ii) about 31% relative to hTR-beta; (iii) about 25% relative to hGR; and (iv) about 33% relative to hRXR-alpha; or D. (i) about 27% relative to hRAR-alpha; (ii) about 24% relative to hTR-beta; (iii) about 20% relative to hGR; and (iv) about 29relative to hRXR-alpha; or E. (i) about 24% relative to hRAR-alpha; (ii) about 28% relative to hTR-beta; (iii) about 18% relative to hGR; and (iv) about 33relative to hRXR-alpha.

19. A polypeptide according to claim 1 wherein said polypeptide has the same amino acid sequence as polypeptides selected from SEQ ID NOS:2, 4, 6, 8, 10, 12 or 14.

20. A chimeric receptor comprising an amino-terminal domain, a DNA-binding domain, and a ligand-binding domain, wherein at least one of the domains thereof is derived from the polypeptide of claim 1; and wherein at least one of the domains thereof is derived from at least one previously identified member of the steroid/thyroid superfamily of receptors.

Non-Patent Literature (4)

Baker et al. PNAS 85(1988) 3294-3298.
Beato Cell 56 (1989) 335-344.
Evans Science 240(1988) 889-895.
Mangelsdorf et al. Nature 345 (1990) 224-229.

Abstract

Description